METTL3 is also an independent predictor of poor prognosis in esophageal and nasopharyngeal cancers [136–138], and is highly expressed and predictive of poor prognostic outcomes in cancers such as glioblastoma and uroepithelial carcinoma of the bladder [110, 139, 140].METTL3 is highly expressed and predictive of poor prognostic outcomes in Kidney renal clear cell carcinoma (KIRC) tissues, and METTL3 expression is significantly upregulated in Kidney renal clear cell carcinoma (KIRC) tissues. Here, METTL3 is linked to glioblastoma.